| scholarly article | Q13442814 |
| P2093 | author name string | Samuel C Mok | |
| Bruce McClane | |||
| Qing Zeng | |||
| Zhijian Gao | |||
| Ross S Berkowitz | |||
| William R Welch | |||
| Babak Litkouhi | |||
| Elizabeth I O Garner | |||
| Xiaoyin Xu | |||
| P2860 | cites work | Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands | Q22008687 |
| The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer | Q24794927 | ||
| Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium | Q28203495 | ||
| Multifunctional strands in tight junctions | Q28210051 | ||
| Cancer statistics, 2009 | Q29547625 | ||
| Three-dimensional culture models of normal and malignant breast epithelial cells | Q30496418 | ||
| Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer | Q31833417 | ||
| Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel | Q33504313 | ||
| Molecular structure of tight junctions and their role in epithelial transport. | Q34302113 | ||
| Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. | Q35098046 | ||
| Differential gene expression in ovarian carcinoma: identification of potential biomarkers | Q35103006 | ||
| Intraperitoneal antineoplastic drug delivery: rationale and results | Q35121705 | ||
| Deletion analysis of the Clostridium perfringens enterotoxin | Q35544215 | ||
| Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin | Q35756974 | ||
| Claudin proteins in human cancer: promising new targets for diagnosis and therapy | Q36305148 | ||
| Orientation of spindle axis and distribution of plasma membrane proteins during cell division in polarized MDCKII cells | Q36534977 | ||
| Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells | Q37200457 | ||
| Localization of the receptor-binding region of Clostridium perfringens enterotoxin utilizing cloned toxin fragments and synthetic peptides. The 30 C-terminal amino acids define a functional binding region | Q38334803 | ||
| Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors | Q39830843 | ||
| Production and characterization of monoclonal antibodies to Clostridium perfringens enterotoxin. | Q40171469 | ||
| An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines | Q40407981 | ||
| Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin | Q40421113 | ||
| Comparative biochemical and immunocytochemical studies reveal differences in the effects of Clostridium perfringens enterotoxin on polarized CaCo-2 cells versus Vero cells | Q40793623 | ||
| Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: Evidence for direct involvement of claudins in tight junction barrier. | Q40925316 | ||
| Evidence for Clostridium perfringens enterotoxin (CPE) inducing a mitogenic and cytokine response in vitro and a cytokine response in vivo | Q40985115 | ||
| Epithelial cells retain junctions during mitosis | Q41577301 | ||
| Up-regulation by IGF-I of proliferating cell nuclear antigen and Bcl-2 protein expression in human uterine leiomyoma cells | Q43794640 | ||
| p53 Tumor suppressor protein content in human uterine leiomyomas and its down-regulation by 17 beta-estradiol | Q44089118 | ||
| A novel strategy for the enhancement of drug absorption using a claudin modulator | Q45188971 | ||
| Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target | Q51019711 | ||
| Role of C-terminal regions of the C-terminal fragment of Clostridium perfringens enterotoxin in its interaction with claudin-4. | Q52565720 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| Differences in expression patterns of the tight junction proteins,claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours. | Q53264168 | ||
| Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. | Q53609842 | ||
| Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. | Q53924073 | ||
| Occludin and claudin-1 concentrate in the midbody of immortalized mouse hepatocytes during cell division | Q73446907 | ||
| Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin | Q73717910 | ||
| Clostridium perfringens enterotoxin as a novel-targeted therapeutic for brain metastasis | Q81097997 | ||
| New insights into the cytotoxic mechanisms of Clostridium perfringens enterotoxin | Q83345892 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| Clostridium perfringens | Q309465 | ||
| carboplatin | Q415588 | ||
| paclitaxel | Q423762 | ||
| P304 | page(s) | 1065-1074 | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | C terminus of Clostridium perfringens enterotoxin downregulates CLDN4 and sensitizes ovarian cancer cells to Taxol and Carboplatin | |
| P478 | volume | 17 |
| Q38761851 | Claudin-4 binder C-CPE 194 enhances effects of anticancer agents on pancreatic cancer cell lines via a MAPK pathway |
| Q38868198 | Claudin-binder C-CPE mutants enhance permeability of insulin across human nasal epithelial cells |
| Q39246243 | Claudin-targeted drug development using anti-claudin monoclonal antibodies to treat hepatitis and cancer. |
| Q35532292 | Claudins 10 and 18 are predominantly expressed in lung adenocarcinomas and in tumors of nonsmokers |
| Q37880969 | Claudins in lung diseases |
| Q26851347 | Claudins overexpression in ovarian cancer: potential targets for Clostridium Perfringens Enterotoxin (CPE) based diagnosis and therapy |
| Q26752971 | Clostridium perfringens Enterotoxin: Action, Genetics, and Translational Applications |
| Q35564030 | Clostridium perfringens enterotoxin (CPE) and CPE-binding domain (c-CPE) for the detection and treatment of gynecologic cancers |
| Q92441177 | Development of Human Monoclonal Antibody for Claudin-3 Overexpressing Carcinoma Targeting |
| Q35971814 | Epithelial-mesenchymal transition in ovarian carcinoma |
| Q57296168 | Functionalization of gold-nanoparticles by the Clostridium perfringens enterotoxin C-terminus for tumor cell ablation using the gold nanoparticle-mediated laser perforation technique |
| Q37377308 | Longitudinal Claudin Gene Expression Analyses in Canine Mammary Tissues and Thereof Derived Primary Cultures and Cell Lines |
| Q36773924 | Overexpression of claudin-4 may be involved in endometrial tumorigenesis |
| Q38821198 | Roles of the first-generation claudin binder, Clostridium perfringens enterotoxin, in the diagnosis and claudin-targeted treatment of epithelium-derived cancers |
| Q38026601 | Targeting claudin-4 in human pancreatic cancer |
| Q38242808 | Targeting tight junctions during epithelial to mesenchymal transition in human pancreatic cancer. |
| Q38811256 | The interaction of Clostridium perfringens enterotoxin with receptor claudins |
| Q38927656 | The role of claudins in cancer metastasis |
| Q34648126 | Transcription factor-microRNA-target gene networks associated with ovarian cancer survival and recurrence |
| Q38199103 | Trends in drug delivery through tissue barriers containing tight junctions. |
| Q35215182 | Use of Clostridium perfringens Enterotoxin and the Enterotoxin Receptor-Binding Domain (C-CPE) for Cancer Treatment: Opportunities and Challenges |
Search more.